In today’s recent session, 27.59 million shares of the Cardiff Oncology Inc (NASDAQ:CRDF) have been traded, and its beta is 1.91. Most recently the company’s share price was $3.73, and it changed around $1.29 or 52.82% from the last close, which brings the market valuation of the company to $190.67M. CRDF at last check was trading at a discount to its 52-week high of $6.42, offering almost -72.12% off that amount. The share price’s 52-week low was $1.25, which indicates that the recent value has risen by an impressive 66.49% since then. We note from Cardiff Oncology Inc’s average daily trading volume that its 10-day average is 0.56 million shares, with the 3-month average coming to 740.66K.
Cardiff Oncology Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 5 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CRDF as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Cardiff Oncology Inc is expected to report earnings per share of -0.26 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Instantly CRDF has been showing a green trend so far today with a performance of 52.82% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.63 on recent trading daydecreased the stock’s daily price by -2.75%. The company’s shares are currently up 151.95% year-to-date, but still up 43.97% over the last five days. On the other hand, Cardiff Oncology Inc (NASDAQ:CRDF) is 21.06% up in the 30-day period. We can see from the shorts that 7.72 million shares have been sold at a short interest cover period of 7.2 day(s).
Cardiff Oncology Inc (CRDF) estimates and forecasts
Cardiff Oncology Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 26.40 percent over the past six months and at a -7.53% annual growth rate that is well below the industry average of 17.10%. The year-over-year growth rate is expected to be 18.81%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 73k in revenue for the current quarter. 4 analysts expect Cardiff Oncology Inc to make 37.5k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 156k and 205k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -53.21%. Forecasts for the next quarter put sales growth at -81.71%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 35.42%.
CRDF Dividends
Cardiff Oncology Inc’s next quarterly earnings report is expected to be released in January.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.60% of Cardiff Oncology Inc shares, and 25.99% of them are in the hands of institutional investors. The stock currently has a share float of 27.82%. Cardiff Oncology Inc stock is held by 111.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 5.883% of the shares, which is about 2.63 million shares worth $5.84 million.
VANGUARD GROUP INC, with 4.7816% or 2.14 million shares worth $4.74 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
